Share, Send, or Save

Pipeline

Alexion is advancing a rare disease pipeline that builds on our fundamental strength in complement biology and focuses on our core therapeutic areas of hematology, nephrology, neurology, and metabolic disorders.

Full Pipeline

Market
Advanced Clinical Development
Early Clinical
Development
Preclinical
Filter by:
 
 
Generate PDF
 

Soliris® (eculizumab) for Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase: Market

 
 

Soliris® (eculizumab) for Atypical Hemolytic Uremic Syndrome (aHUS)
Phase: Market

 
 

Soliris® (eculizumab) for Refractory Generalized Myasthenia Gravis (gMG)
Phase: Market

 
 

Eculizumab for Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD)
Phase: Advanced Clinical Development

 
 

Eculizumab for Antibody Mediated Rejection (AMR)
Phase: Advanced Clinical Development

 
 

ALXN1210 for PNH
Phase: Advanced Clinical Development

 
 

ALXN1210 for aHUS
Phase: Advanced Clinical Development

 
 

ALXN1210—Subcutaneous
Phase: Early Clinical Development

 
 

ALXN1210 New Indications
Phase: Early Clinical Development

 
 

Strensiq® (asfotase alfa) for Hypophosphatasia (HPP)
Phase: Market

 
 

Kanuma® (sebelipase alfa) for Lysosomal Acid Lipase Deficiency (LAL-D)
Phase: Market

 
 

Multiple Complement
Phase: Preclinical